Wir sind mit live! Mehr erfahren

enGene Therapeutics

ENGN

Börsenwert 112 Mio. $

1,67 USD

-0,04

2,34 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

1,70

+0,03

1,8 %

1 Tag

-2,34 %

5 Tage

-3,47 %

1 Monat

-12,57 %

3 Monate

-13,02 %

6 Monate

-79,33 %

Seit Jahresbeginn

-81,13 %

1 Jahr

-81,02 %

5 Jahre

-91,65 %

10 Jahre

-91,65 %

Profil: enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.

Mitarbeiter: 82

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 0 %

Neutral 90 %

Negativ 10 %

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path

enGene NASDAQ: ENGN used a company webinar to outline preclinical findings for its investigational non-viral gene therapy, detalimogene voraplasmid, used with a polidocanol surfactant bladder rinse, while community urologists discussed the treatment burden facing patients with high-risk non-muscle invasive bladder cancer, or NMIBC.

enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment Transcript

enGene to Host KOL Webinar on October 15, 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a webinar on Thursday, October 15, 2026 at 10:00 AM ET that will provide greater detail on the preclinical data supporting the incorporation of its surfactant bladder rinse plus detalimogene voraplasmid (detalimogene) into clinical development for Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk, no.

enGene to Host KOL Webinar on October 15, 2026

enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

enGene Therapeutics remains deeply undervalued, trading below its $3.97/share cash position despite pipeline and execution risks. ENGN's lead asset, detalimogene voraplasmid, faces FDA approval risk due to weak 12-month durability, but management is pursuing a surfactant cohort to address efficacy. Cost-saving measures, including a 50% workforce reduction, extend ENGN's cash runway into 2029, supporting operations through pivotal BLA milestones.

enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the third quarter ended July 31, 2026, and provided clinical and corporate updates. “As we move through the second half of 2026, our focus is on maturing regulatory endpoints data from LEGEND's pivotal cohort and our planned engagement with the FDA regarding a BLA filing for detalimogene," said Ro.

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update

enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference Date: Tuesday, September 8, 2026 Time: 10:15 a.m. ET Format: Fireside Chat Morgan Stanley 24th Annual Global Healthcare Conference Date: Monday, September 14, 2026 Time: 7:00 a.m. ET Format: Fireside Chat H.

enGene to Participate in Upcoming Investor Conferences

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene NASDAQ: ENGN outlined its view of the high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer, or NMIBC, market, citing market research that it believes supports a larger addressable patient population and greater use of treatment sequencing before radical cystectomy.

enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene Therapeutics Inc. (ENGN) Discusses Market Insights and Clinical Development in Non-Muscle Invasive Bladder Cancer Transcript

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, August 11, 2026 at 11:00 AM ET featuring Neal Shore, MD, FACS (Carolina Urologic Research Center; Atlantic Urology Clinics). Dr. Shore will join management to provide insights into the evolving NMIBC treatment landscape and the various considerations dr.

enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt